FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Verbeke, Len, Mannaerts, Inge, Schierwagen, Robert, Govaere, Olivier, Klein, Sabine, Vander Elst, Ingrid, Windmolders, Petra, Farre, Ricard +6 more·2016·Scientific Reports
DOI 10.1038/srep33453

Cited by (238)

Items 201–238 of 238

  1. Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension
    Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas A. Capozza, Jing Li, Radhika Nair, Michael A Trauner, David E. Jones · 2026 · Alimentary Pharmacology & Therapeutics
  2. Liver sinusoidal endothelial cells in liver diseases and hepatocellular carcinoma: molecular mechanisms, physiology, and therapies
    Meng-Yao Yan, Yi-Min Cui, Qian Xiang · 2026 · Molecular Biomedicine
  3. Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
    Anabel Fernández‐Iglesias, Jordi Gracia‐Sancho · 2024 · Elsevier eBooks
  4. Saroglitazar - A novel treatment for non-alcoholic steatohepatitis
    Shifa Noorani, Manasa Ankam, C. H. S. V. Ganesh, Rahnuma Banu, Parmar Vani, Naveen Polarapu, Sarita Jangra, K. A. Shaima, Bhupinder Bhyan · 2024 · AIP conference proceedings
  5. Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
    Sukhraj Singh, KK Kharbanda · 2017 · Archives of Hepatitis Research
  6. Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators
    Christina Lamers, Daniel Merk · 2020 · Royal Society of Chemistry eBooks
  7. A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
    Robert Schierwagen, Sabine Klein, Jonel Trebicka · 2020 · Cellular and Molecular Gastroenterology and Hepatology
  8. Umbilical Cord Mesenchymal Stem/Stromal Cells and Low-Dose Obeticholic Acid as a Possible Combined Treatment for Liver Fibrosis
    Ahmed Lotfy, Shimaa El-Metwaly, Reham Soliman, Ayman Hassan, Gamal El-Sayed Shiha · 2022 · Stem Cell Reviews and Reports
  9. Investigational drugs in early clinical development for portal hypertension
    Susana Gomes Rodrigues, Yuly Paulin Mendoza, Jaime Bosch · 2022 · Expert Opinion on Investigational Drugs
  10. Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
    Wenkang Gao, Zhonglin Li, Huikuan Chu, Hang Yuan, Lilin Hu, Lin Yao, Li Rita Zhang, Weijun Wang, Rong Lin, Ling Yang · 2022 · Springer eBooks
  11. Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis
    Robert Schierwagen, Frank Erhard Uschner, Sabine Klein, Jonel Trebicka · 2016 · Current Hepatology Reports
  12. The Impact of Gut Microbiota on Liver Injury
    Wenke Feng, Craig James McClain · 2017 · Springer eBooks
  13. REGULATION OF UBIQUITIN SPECIFIC PEPTIDASE 2 EXPRESSION BY FARNESOID X RECEPTOR IN HEPATOCELLULAR CARCINOMA
    Christina Nadolny · 2018
  14. Primary biliary cholangitis: an update on treatment
    Fatima Bibi · 2018 · Gastrointestinal Nursing
  15. Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed
    Vlad Ratziu · 2020 · Hepatology
  16. Pharmacological Options for NASH
    Christiane Stern, Vlad Ratziu · 2020 · Springer eBooks
  17. Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms
    Marek Rác, Ľubomír Skladaný · 2018 · Vnitřní lékařství
  18. Repositioning of a Novel GABA-B Receptor Agonist, AZD3355 (Lesogaberan), for the Treatment of Non-alcoholic Steatohepatitis
    Dipankar Bhattacharya, Christine Becker, Benjamin P. Readhead, Nicolas Goossens, Jacqueline L. Buros, Maria Isabel Fiel, Leslie P. Cousens, Björn Magnusson, Anna Backmark, Ryan Hicks et al. · 2021 · Research Square
  19. MedBulletin
    Daniel G. Rayner, Shadi Sadeghian · 2020 · The Meducator
  20. Postoperative liver (dys)function
    Kim M.C. van Mierlo · 2022
  21. Pathopysiologie: Insulinresistenz
    Johannes Kluwe · 2022 · Springer eBooks
  22. The FXR agonist obeticholic acid does not stimulate liver regeneration in hepatectomized mice
    Kim M.C. van Mierlo, Carola Dahrenmöller, Valérie Lebrun, Peter L. M. Jansen, Cornelis H.C. Dejong, Isabelle Anne Leclercq, Steven W.M. Olde Damink, Frank G. Schaap · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  23. A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants
    Rowan A. Stringer, Jin Chen, Bharti Shah, Jessie Gu, Yiming Zhang, William Prince, Lloyd B. Klickstein, Ralph Woessner · 2022 · Clinical Pharmacology in Drug Development
  24. Drugs to Modify Liver Fibrosis Progression and Regression
    Marina Vilaseca, Jordi Gracia‐Sancho · 2022 · Springer eBooks
  25. Obeticholic acid treatment of mice to promote fertilization and reproduction
    Ming Liang, Huailiang Yang, Lanyong Xu, Longqiao Cao · 2023 · Zygote
  26. Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System
    Justin J. Odanga, Sharon M. Anderson, Edward L. LeCluyse, Sharon Collins Presnell, Jingsong Chen, Jessica R. Weaver · 2025 · Cells
  27. Si-Ni-San improves the deposition of lipid droplets in MAFLD through modulating the FXR-GPAT4 axis
    Haibo Fan, Yalei Hou, Yue Li, Zhiwen Zheng, Xuelun Wang, Yunfeng Li, Yongmin Li · 2026 · Chinese Medicine
  28. Comparative study of obeticholic acid and rosuvastatin in high-fat/fructose diet–induced metabolic dysfunction: role of AMPK, PPAR-γ, SREBP-1c, and STAT3 pathways
    Sahar M. Elashmony, Yosra Zakariyya Alhindi, Dina H. Merzeban, Rehab A. Mohammed, Asmaa Mohamed Elsayed, Mariham George Loqa, Rania Hosny Mahmoud, Hanan Abdelmoneam Shamardl, Mona Farag Shabana · 2026 · Journal of Molecular Histology
  29. Revisiting cholesterol metabolism in hepatocellular carcinoma: a hidden driver of systemic therapy response
    Lara M. Stoffels, E.S. Espinoza Rodriguez, Jan Theys, Ronit Shiri‐Sverdlov · 2026 · ESMO Gastrointestinal Oncology
  30. Implication du microbiote intestinal humain dans l‘évolution des hépatopathies métaboliques non liées à l’alcoolisme (NAFLD)
    Sebastian D. Burz · 2020 · theses.fr (ABES)
  31. The bile acid-FXR axis as a critical target and mediator of pesticide-induced toxicity: Mechanisms and implications for hazard assessment
    Xing-Jian Guo, Li’ou Zhu, Xianpeng Zhou, Chenxi Liang, Xiao-Lin Zhang, Chen Wang, Biao Yan · 2026 · Journal of Hazardous Materials Advances
  32. Unraveling the oxidative stress inflammation nexus in metabolic syndrome and therapeutic opportunities
    Priscilla Oluwabusayomi Ojo, Damilare Emmanuel Rotimi, Emmanuel Henry Ezenabor, Musbau Adewumi Akanji, Oluyomi Stephen Adeyemı · 2026 · Discover Medicine
  33. Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways
    Fares E.M. Ali, Adel G. Bakr, Abdel‐Gawad S. Shalkami, Ehab A. M. El‐Shoura, Lamiaa Khalaf Ahmed, Ali F. Abd‐Elsalam, Ahmed A. N. Ahmed, Emad H. M. Hassanein · 2026 · Journal of Biochemical and Molecular Toxicology
  34. A refined MASH–HCC model identifies macrophage Gadd45b as a key orchestrator of inflammation-driven neoplastic progression
    Hyunmi Kim, Gyeonghun Kim, Hyojin Yeon, Da-Yeon Yang, Sang Gyu Lee, Tae Hyeon An, Seung Yeon Oh, Seona Yoon, Jiwoo Kim, Juyong Choi et al. · 2026 · Experimental & Molecular Medicine
  35. Obeticholic acid attenuates complete freund’s adjuvant-induced arthritis in rats through FXR-mediated modulation of TGF-β/TAK1/MKK3/p38 MAPK signaling, inflammation, and oxidative stress
    Mohamed Magdy Senna, Nesma A. Shiha, Hala Fahmy Zaki, Laila A. A. Ramadan, Aya M. Mustafa · 2026 · Inflammopharmacology
  36. A Long-Acting Farnesoid X Receptor (FXR) Agonist Prevents Fibrosis
    Ashrafi Sultana, Grace A Bybee, Anup Singh Pathania, Weimin Wang, Nam Thai Hoang Le, Brandon W. Hanson, Christopher D. Bauer, Deanna D. Mosley, Howard Eliot Gendelman, Samuel M. Cohen et al. · 2026 · Biomolecules
  37. BindingDB Entry 50001913: Andrographolide derivative as STAT3 inhibitor that protects acute liver damage in mice.
    BindingDB · 2020 · UC San Diego
  38. BindingDB Entry 50009310: Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    BindingDB · 2021 · UC San Diego